James R. McCullough has spent the majority of his career in translational medicine, working with leading academic medical centers and healthcare investors in the United States and Europe to drive commercialization of critical research discoveries in individualized medicine. Mr. McCullough is currently Chief Executive Officer of Exosome Diagnostics, Inc., a developer of a new generation of gene-based diagnostics derived from ground-breaking research conducted at Massachusetts General Hospital and Harvard University in the blood of brain cancer patients. Exosome Diagnostics technology allows for highly sensitive detection of key gene mutations in biofluids for more accurate diagnosis of cancer and monitoring tumor response to therapeutic treatment without the need for a tissue biopsy.
Previously, Mr. McCullough was Chief Executive Officer of AusAm Biotechnologies, Inc., a developer of diagnostics to identify kidney and cardiovascular diseases. He received his BA from Boston University in 1990 and his MBA from the Columbia Graduate School of Business in 1995.
Mr. McCullough is a member of the Board of Directors of Papivax, a developer of HPV vaccination technology from John's Hopkins University, and Genospace, a genetic repository and analysis system developed at Dana Farber Cancer Institute. He also acts as an advisor to different translational projects in the field of individualized medicine.
In addition, Mr. McCullough is a member of Board of Directors of Youth America Grand Prix, the world's largest ballet education and competition organization.